NCT07015671View on ClinicalTrials.gov

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

PHASE3RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Bioequivalence Study in Healthy SubjectsPK/PD
Interventions
DRUG

10 mg Torsemide tablet

Single dose 10 mg Torsemide tablet

DRUG

25 mg Aldactone (Spironolactone) tablet

Single dose 25 mg Aldactone® (Spironolactone) tablet

DRUG

FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet

Single dose FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet

Trial Locations (1)

22182

RECRUITING

Sarfez Pharmaceuticals, Vienna

All Listed Sponsors
lead

Sarfez Pharmaceuticals, Inc.

INDUSTRY